Welcome to our dedicated page for Humacyte news (Ticker: HUMA), a resource for investors and traders seeking the latest updates and insights on Humacyte stock.
Humacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform company developing universally implantable, bioengineered human tissues at commercial scale. Its news flow centers on Symvess, an FDA-approved acellular tissue engineered vessel (ATEV™) for extremity arterial injury when autologous vein graft is not feasible, and on the broader clinical and regulatory progress of its ATEV pipeline.
On this page, readers can follow HUMA news related to vascular trauma, hemodialysis access, peripheral artery disease, and other vascular indications where Humacyte’s acellular tissue engineered vessels are being studied. Company announcements frequently cover clinical trial readouts, such as Phase 2/3 and Phase 3 data in trauma and dialysis access, long-term safety and efficacy publications in peer-reviewed journals, and presentations at major medical meetings including the VEITHsymposium and the American Society of Nephrology’s Kidney Week.
Humacyte also issues updates on healthcare economics analyses in extremity arterial injury, highlighting the cost impact of complications like amputation and conduit infection and positioning Symvess as an alternative when vein is not feasible. Additional news items describe humanitarian and real-world use of Symvess in wartime vascular injuries, as well as outcomes in hospital-acquired vascular complications and high-risk patient subgroups.
Investors and clinicians can use this HUMA news feed to track regulatory milestones, such as the FDA approval of the ATEV in vascular trauma, RMAT and Fast Track designations, and planned marketing authorization applications in new territories. Financial and corporate updates, including credit facilities, registered offerings, and sales agreements, are also reported through company press releases and Form 8-K filings. Bookmark this page for an organized view of Humacyte’s latest disclosures on its bioengineered tissue platform, commercial launch activities for Symvess, and ongoing pipeline development.
Humacyte has published five-year data from a Phase 2 trial of its Human Acellular Vessel (HAV), demonstrating its potential as a durable, safe option for vascular access in long-term hemodialysis patients. The study showed a 58.2% patency rate at five years, significantly higher than the historical 30% for arteriovenous fistulas. No infections were reported, indicating strong safety and tolerability. Humacyte is currently conducting a Phase 3 trial involving up to 240 patients to further evaluate HAV's usability compared to traditional fistulas.
Humacyte, a biotechnology company listed on Nasdaq: HUMA, will have its CEO Laura Niklason and CFO Dale Sander participating in a virtual fireside chat at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference on February 15, 2022, at 9 a.m. EST. This event highlights Humacyte's innovative work in developing universally implantable bioengineered human tissues and organs, particularly its human acellular vessels, currently undergoing late-stage clinical trials for various medical applications.
Humacyte, Inc. (Nasdaq: HUMA) presented outcomes from eight compassionate use cases of its Human Acellular Vessel (HAV) at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society. The HAVs demonstrated efficacy in maintaining patency and resisting infection in patients with critical limb ischemia and vascular trauma, who had no suitable alternative treatment options. Five bypasses remained patent after follow-ups from four to 20 months. The HAV is engineered to be an off-the-shelf solution for vascular repair, currently under FDA evaluation.
Humacyte, Inc. (Nasdaq: HUMA) announced promising results from its preclinical study on the 3.5mm Human Acellular Vessel (HAV) for coronary artery bypass grafting (CABG), presented at Advanced Therapies Week 2022. The study showed that the HAVs maintained patency and supported host-cell remodeling in a non-human primate model over six months. This advancement could eliminate the need for vein harvesting, which is critically important in CABG procedures. Humacyte aims to further assess safety and efficacy to facilitate future clinical trials.
Humacyte, Inc. (Nasdaq: HUMA) announced that the results of its first compassionate use cases of the Human Acellular Vessel (HAV) will be presented at the 46th Annual Winter Meeting of the Vascular and Endovascular Surgery Society on January 28, 2022. The study reports outcomes from eight patients with critical limb ischemia who underwent HAV implantation, providing new insights into limb salvage options. The HAVs are in late-stage trials for various vascular applications, emphasizing their significance for patients with limited treatment alternatives.
Humacyte (Nasdaq: HUMA) has announced pivotal preclinical results for its Human Acellular Vessel™ (HAV) in coronary artery bypass grafting (CABG), to be presented at the Advanced Therapies Week conference on January 28, 2022. The HAVs are designed to address the significant need for viable vascular substitutes, especially in patients lacking suitable autologous veins. Over 350,000 CABG surgeries occur annually in the U.S. alone, indicating a substantial market opportunity. This development represents a critical milestone in advancing small-diameter HAVs for CABG procedures.
Humacyte, Inc. (Nasdaq: HUMA) has appointed renowned Surgical Key Opinion Leaders Alan P. Kypson, Luigi Pascarella, and Todd E. Rasmussen to advisory positions to enhance their clinical and educational efforts regarding the Human Acellular Vessel (HAV). The HAV, currently in advanced clinical trials for vascular trauma and other ailments, aims for commercialization in initial vascular indications. These experts will guide the company's pipeline advancements and support its growth strategy in regenerative medicine.
Humacyte, Inc. (Nasdaq: HUMA) announced a published case study on the use of its human acellular vessel (HAV) for treating an infected synthetic vascular graft. The case involved a 42-year-old female patient at Vanderbilt University Medical Center, who showed significant improvement 22 months post-implantation, with no signs of infection. The HAV has been utilized in 20 cases under the FDA’s Expanded Access Program. Humacyte continues to evaluate the HAV in clinical trials for various vascular applications, with over 460 implants performed to date.
Humacyte, Inc. (Nasdaq: HUMA) announced positive results from a preclinical study of its 3.5mm Human Acellular Vessel (HAV) during the American Heart Association’s 2021 Scientific Sessions. The study involved five juvenile primates, showing that all HAVs remained patent and were repopulated with vascular cells over three to six months. Two primates displayed mid-graft dilatations due to a xenogeneic response. The study supports the potential application of HAVs in pediatric heart surgeries and advances Humacyte’s broader vascular platform, indicating successful bioengineering capabilities for small-diameter vessels.
Humacyte announced positive results from a Phase 2 clinical trial of its human acellular vessels (HAVs), produced using the commercial-scale LUNA200 system, showing 83% secondary patency at 12 months post-implantation. The study included 30 end-stage renal disease patients undergoing hemodialysis. Key findings indicate no instances of HAV rupture or failure, and that the LUNA200 platform functions comparably to previous systems. The fully operational facility in Durham, N.C. supports an annual capacity of approximately 40,000 HAVs.